Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact

M MacLeod, A Papi, M Contoli, B Beghé, BR Celli… - …, 2021 - Wiley Online Library
In chronic obstructive pulmonary disease (COPD), exacerbations (ECOPD), characterized
by an acute deterioration in respiratory symptoms, are fundamental events impacting …

Exacerbations of COPD

C Viniol, CF Vogelmeier - European Respiratory Review, 2018 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death
worldwide. While COPD is a mainly chronic disease, a substantial number of patients suffer …

Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary

CF Vogelmeier, GJ Criner, FJ Martinez… - American journal of …, 2017 - atsjournals.org
This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …

Implications of race adjustment in lung-function equations

JA Diao, Y He, R Khazanchi, MJN Tiako… - The New England …, 2024 - pmc.ncbi.nlm.nih.gov
BACKGROUND Adjustment for race is discouraged in lung-function testing, but the
implications of adopting race-neutral equations have not been comprehensively quantified …

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel …

J Vestbo, A Papi, M Corradi, V Blazhko, I Montagna… - The Lancet, 2017 - thelancet.com
Background Limited data are available for the efficacy of triple therapy with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …

Impact and prevention of severe exacerbations of COPD: a review of the evidence

DMG Halpin, M Miravitlles, N Metzdorf… - International journal of …, 2017 - Taylor & Francis
Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …

An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease

BR Celli, M Decramer, JA Wedzicha… - American journal of …, 2015 - atsjournals.org
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of
morbidity, mortality, and resource use worldwide. The goal of this Official American Thoracic …

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active …

PMA Calverley, AR Anzueto, K Carter… - The Lancet …, 2018 - thelancet.com
Background Combinations of long-acting bronchodilators are recommended to reduce the
rate of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear whether …

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive …

M Decramer, A Anzueto, E Kerwin, T Kaelin… - The Lancet …, 2014 - thelancet.com
Background Combination long-acting bronchodilator treatment might be more effective than
long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary …

Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial

N Roche, KR Chapman, CF Vogelmeier… - American journal of …, 2017 - atsjournals.org
Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive
biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive …